Ben Wallace’s strategic M&A move marks a new chapter in global dealmaking

The recent announcement of Ben Wallace as co-head of Mergers and Acquisitions (M&A) in the Americas at Goldman Sachs in 2025 marks a significant strategic move for the firm, indicating a heightened emphasis on healthcare and cross-border transactions. Wallace, who also serves as the global head of healthcare M&A, has been positioned to take advantage of a rapidly growing sector while showcasing the company’s commitment to regional dealmaking. This shift comes at a time when healthcare M&A activities are on the rise due to various factors such as aging populations, technological advancements, and regulatory changes. Let’s delve into what this means for investors.

Wallace’s appointment is backed by his impressive track record, having been involved in transactions totaling over $700 billion, including major deals like the $30 billion leveraged buyout of Medline Industries and the $16.4 billion sale of Varian to Siemens Healthineers. His role in the $8 billion CVS Health acquisition of Signify Health demonstrates his ability to navigate complex regulatory landscapes successfully. These transactions not only benefit clients but also solidify Goldman’s reputation as a premier healthcare M&A advisor. Historically, Goldman’s stock has demonstrated growth during periods of active M&A activity, with its market cap increasing by $15.06 billion in the first quarter of 2025. Investors are advised to monitor quarterly reports on GS’s M&A revenue to gauge its momentum.

The healthcare sector is undergoing significant growth, driven by factors such as an aging population, increasing demand for digital health solutions, and consolidation within biopharma and medical devices. This sector is witnessing trends like the merger of startups and traditional companies to leverage AI diagnostic tools and telehealth platforms. Furthermore, changes in regulatory policies post-pandemic are accelerating deals in areas like data privacy and drug pricing. Lower interest rates and narrowing valuation gaps are making healthcare targets more appealing to private equity firms. Wallace’s dual role allows him to connect global healthcare trends with regional opportunities, as evidenced by his involvement in Holcim’s recent spin-off of Amrize, a healthcare services company listed on the NYSE.

While cross-border M&A activities in the Americas are a key focus, there are risks involved, including geopolitical tensions and regulatory challenges like antitrust scrutiny. However, Wallace’s experience in structuring complex transactions, such as the Siemens Healthineers acquisition, indicates his ability to navigate these obstacles. Data reflects an 18% growth in healthcare M&A volume in the Americas in 2024, with cross-border transactions accounting for 35% of the total, supporting the strategic timing of Wallace’s appointment.

Investors should consider opportunities in healthcare enablers like Cigna and UnitedHealth Group, potential IPO candidates like Medline Industries, and the direct impact of healthcare deal flow on Goldman Sachs’ investment banking revenue. While risks such as regulatory constraints and economic downturns exist, following the trends in healthcare M&A and Wallace’s leadership can offer valuable insights for long-term investments. In conclusion, the alignment of market trends and Goldman’s expertise positions the healthcare sector as a compelling avenue for exploration, underscoring the importance of monitoring developments in the industry and the firm under Wallace’s guidance.